嘧啶-2-羧酸 | 31519-62-7

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 嘧啶-2-羧酸
• 中文别名: 2-嘧啶甲酸
• 英文名称: pyrimidine-2-carboxylic acid
• 英文别名: 2-pyrimidine carboxylic acid；2-carboxypyrimidine；Pyrimidin-2-carbonsaeure
• CAS: 31519-62-7
• 化学式: C₅H₄N₂O₂
• 分子量: 124.099
• InChiKey: ZFCHNZDUMIOWFV-UHFFFAOYSA-N

物化性质

• 熔点：
  182-185°C
• 沸点：
  362.6±25.0 °C(Predicted)
• 密度：
  1.403±0.06 g/cm3(Predicted)
• 溶解度：
  溶于乙醇、二甲基亚砜(DMSO)、二甲基甲酰胺(DMF)和磷酸盐缓冲盐水(PBS)溶液。
• 最大波长(λmax)：
  246nm(H2O (pH 7))(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933599090
• 危险品运输编号：
  NONH for all modes of transport
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
pyrimidine-2-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
pyrimidine-2-carboxylic acid
Ingredient name:
CAS number: 31519-62-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4N2O2
Molecular weight: 124.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  嘧啶-2-羧酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N,N-diethylpyrimidine-2-carboxamide
  参考文献：
  名称：

  电子不足的杂芳烃盐：氧化中过氧化氢活化的有机催化工具

  摘要：

  制备了一系列的单取代的嘧啶鎓和吡嗪鎓三氟甲磺酸酯和3,5-二取代的吡啶鎓三氟甲磺酸酯，并使用硫氧化作为模型反应，对过氧化氢的简单氧化催化剂进行了测试。它们的催化效率在很大程度上取决于取代基的类型，并且对于具有吸电子基团的衍生物而言是显着的，其反应性与黄酮盐相当，后者是氧合作用的主要有机催化剂。由于它们的高稳定性和良好的可及性，4-（三氟甲基）嘧啶鎓和3,5-二硝基吡啶鎓三氟甲磺酸盐是选择的催化剂，并显示出催化脂肪族和芳香族硫化物氧化为亚砜的作用，定量转化率高，制备产率高，并且具有优异的性能。化学选择性。K R +值（p K R + <5）和较小的负还原电位（E red > -0.5 V）。在催化氧化过程中原位形成的过氧化氢加合物充当底物氧化剂。通过在B3LYP / 6-311 ++ g（d，p）水平上的计算获得的从这些杂环氢过氧化物到硫代苯甲醚的转移的吉布斯自由能表明，它们是比烷基氢过氧化

  DOI：

  10.1021/jo502865f
• 作为产物：
  描述：

  2-[(E)-2-苯基乙烯基]嘧啶 在 potassium permanganate 作用下， 生成 嘧啶-2-羧酸
  参考文献：
  名称：

  Holland, Chemistry and industry, 1954, p. 786

  摘要：

  DOI：

文献信息

• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。
• Copper iodide nanoparticles‐decorated porous polysulfonamide gel: As effective catalyst for decarboxylative synthesis of <i>N</i> ‐Arylsulfonamides
  作者：Sedigheh Alavinia、Ramin Ghorbani‐Vaghei、Jamshid Rakhtshah、Jaber Yousefi Seyf、Iman Ali Arabian

  DOI：10.1002/aoc.5449

  日期：2020.3

  A porous cross‐linked poly (ethyleneamine)‐polysulfonamide (PEA‐PSA) as a novel organic support system is synthesized in the presence of silica template by nanocasting technique. The paper demonstrates immobilization of CuI nanoparticles inside the pores (PEA‐PSA@CuI) for the facile recovery and recycling of these nanoparticles. The presence of porous PEA‐PSA and PEA‐PSA@CuI nanocomposites was confirmed

  在二氧化硅模板的存在下，通过纳米浇铸技术合成了一种多孔的交联聚（亚乙基胺）-聚磺酰胺（PEA-PSA）作为一种新型的有机载体体系。本文证明了将CuI纳米粒子固定在孔内（PEA-PSA @ CuI）可以方便地回收和再循环这些纳米粒子。使用FT-IR光谱，FE-SEM，EDX，TGA，XRD，TEM，BET，XPS，WDX，1 H NMR和ICP-OES技术确认了多孔PEA-PSA和PEA-PSA @ CuI纳米复合材料的存在。PEA-PSA @ CuI与Ag（I）/ K 2 S 2 O 8一起作为p的N-芳基化中可重复使用的协同催化剂-氧化剂体系而实现-甲苯磺酰胺与温和的取代羧酸。因此，已经开发了由铜和银催化的新型脱羧交叉偶联。芳族，仲和叔脂肪酸与对甲苯磺酰胺经过高效脱羧过程，得到相应的产物。该方法为从容易负担的底物上灵活合成磺酰胺提供了一种实用的方法。该催化剂是高度可重复使用和有效的，特别是在所需产物的时间和产率方面。
• Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment
  作者：Yu Lei、Bing Zhang、Yan Zhang、Xiwen Dai、Yulin Duan、Qing Mao、Jun Gao、Yuwei Yang、Ziyang Bao、Xuefeng Fu、Kunqi Ping、Chengda Yan、Yanhua Mou、Shaojie Wang

  DOI：10.1016/j.ejmech.2021.113437

  日期：2021.8

  weak in vitro factor XIa binding affinity. Under the guide of molecular modeling, we adopted molecular hybridization strategy to develop novel factor XIa inhibitors with WSJ-557 as an initial compound. This led to the identification of the most potent compound 44g with a Ki value of 0.009 μM, which was close to that of BMS-724296 (Ki = 0.0015 μM). Additionally, serine protease selectivity study indicated

  因子XIa，作为一种凝血酶，放大凝血级联中最后一种酶凝血酶的产生。事实证明，直接抑制 XIa 因子可以减少病理性血栓形成，而不会增加出血风险。WSJ-557是我们之前报道中的一种非嘌呤咪唑类黄嘌呤氧化酶抑制剂，在其动物实验中可以延迟血液凝固，这促使我们研究其作用机制。随后，在探索作用机制的过程中，发现WSJ-557在体外表现出弱的XIa因子结合亲和力。在分子建模指导下，我们采用分子杂交策略开发新型因子XIa抑制剂WSJ-557作为初始化合物。这导致鉴定出最有效的化合物44g，其 Ki 值为 0.009 μM，接近BMS-724296（Ki = 0.0015 μM）。此外，丝氨酸蛋白酶选择性研究表明，化合物44g在凝血级联反应中显示出所需的选择性，是凝血酶、因子 VIIa 和因子 Xa 的 400 倍以上。此外，酶动力学研究表明，代表性化合物44g 可作为 FXIa 的竞争型抑制剂，分子模型显示它可以与因子
• [EN] PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT<br/>[FR] INHIBITEUR DE PROTÉINE KINASES ET MÉTHODES DE TRAITEMENT
  申请人：INST MEDICAL W & E HALL

  公开号：WO2012003544A1

  公开（公告）日：2012-01-12

  The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

  本发明涉及化合物的化学式(I)以及其使用和制备方法。具体而言，本发明涉及基于取代的吡唑并[3,4-d]嘧啶的化合物，可用于治疗增殖性疾病，这些化合物在治疗方法中的使用以及药物的制造，以及含有这些化合物的组合物。
• [EN] IMIDAZOTRIAZINONE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOTRIAZINONE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2013142269A1

  公开（公告）日：2013-09-26

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

  本发明提供了咪唑三唑酮化合物，它们是磷酸二酯酶9的抑制剂及其药用盐。本发明还提供了用于治疗哺乳动物，包括人类，PDE9相关疾病或疾病的过程、药物组成、药物制剂和化合物的药用。